Roche Holdings Will Likely See Steady Earnings Growth Despite Loss Of Patents For Key Drugs |
| August 02, 2018 | August 2018 Bond Updates |
|
Roche Holdings (NASDAQ:RHHBY) recently posted its Q2 results, which were more or less in line with estimates. The company’s overall revenues grew 7%, led by a continued ramp up in Ocrevus, and Perjeta sales. Ocrevus, which is a new drug, has seen strong demand of late, and marks the best launch... |
| View more at: https://www.forbes.com/sites/greatspeculations/2018/08/01/roche-holdings-will-likely-see-steady-earnings-growth-despite-loss-of-patents-for-key-drugs/ |
| Related News |
|